NORTHSTAR ASSET MANAGEMENT Co LLC Has $237,000 Holdings in Bristol-Myers Squibb (NYSE:BMY)

NORTHSTAR ASSET MANAGEMENT Co LLC trimmed its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 6.6% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,698 shares of the biopharmaceutical company’s stock after selling 400 shares during the quarter. NORTHSTAR ASSET MANAGEMENT Co LLC’s holdings in Bristol-Myers Squibb were worth $237,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Gradient Investments LLC raised its position in shares of Bristol-Myers Squibb by 9.1% during the second quarter. Gradient Investments LLC now owns 5,393 shares of the biopharmaceutical company’s stock worth $224,000 after purchasing an additional 449 shares during the period. Brookstone Capital Management raised its position in shares of Bristol-Myers Squibb by 0.6% during the second quarter. Brookstone Capital Management now owns 150,895 shares of the biopharmaceutical company’s stock worth $6,511,000 after purchasing an additional 858 shares during the period. Rovin Capital UT ADV raised its position in shares of Bristol-Myers Squibb by 141.7% during the second quarter. Rovin Capital UT ADV now owns 12,870 shares of the biopharmaceutical company’s stock worth $534,000 after purchasing an additional 7,546 shares during the period. Stanley Laman Group Ltd. raised its position in shares of Bristol-Myers Squibb by 42.1% during the second quarter. Stanley Laman Group Ltd. now owns 9,010 shares of the biopharmaceutical company’s stock worth $374,000 after purchasing an additional 2,670 shares during the period. Finally, Blue Trust Inc. raised its position in shares of Bristol-Myers Squibb by 23.7% during the second quarter. Blue Trust Inc. now owns 17,003 shares of the biopharmaceutical company’s stock worth $706,000 after purchasing an additional 3,263 shares during the period. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock traded up $0.25 on Friday, hitting $49.36. 14,161,770 shares of the stock were exchanged, compared to its average volume of 15,904,074. The company has a current ratio of 1.16, a quick ratio of 0.99 and a debt-to-equity ratio of 2.86. The firm has a market capitalization of $100.06 billion, a PE ratio of -15.92, a P/E/G ratio of 12.51 and a beta of 0.44. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.41. The firm’s 50 day moving average is $43.74 and its two-hundred day moving average is $46.58.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 earnings per share for the quarter, topping the consensus estimate of $1.64 by $0.43. The company had revenue of $12.20 billion during the quarter, compared to the consensus estimate of $11.54 billion. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.75 EPS. Sell-side analysts expect that Bristol-Myers Squibb will post 0.77 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Shareholders of record on Friday, July 5th were paid a $0.60 dividend. The ex-dividend date was Friday, July 5th. This represents a $2.40 annualized dividend and a yield of 4.86%. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on BMY shares. TD Cowen increased their price target on Bristol-Myers Squibb from $45.00 to $53.00 and gave the company a “hold” rating in a research report on Monday, August 12th. BMO Capital Markets lowered their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research report on Friday, April 26th. Barclays lowered Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and set a $41.00 price target for the company. in a research report on Monday, July 29th. Deutsche Bank Aktiengesellschaft lowered their price target on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. Finally, StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $54.86.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.